Pharmaceuticals — US PTAB Patent Cases
89 decisions indexed
Page 3 of 3 · 89 total
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR against Helsinn Healthcare's '515 patent covering anti-emetic agents. The Board found a reasonable likelihood of prevailing based on obviousness (103) and prior art, allowing the challenge to proceed.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB that multiple claims of Helsinn Healthcare's anti-emetic patent were unpatentable. The Board granted institution based on obviousness (103) over several prior art references, paving the way for a full trial.
United Therapeutics Corporation v.Actelion Pharmaceuticals Ltd. et al.
The PTAB denied institution for IPR2025-01139, preventing United Therapeutics Corporation from challenging Actelion's patent 8268847.
Fresenius Kabi SwissBiosim, GmbH et al. v.Regeneron Pharmaceuticals, Inc.
The PTAB denied institution of the IPR in a dispute between Fresenius Kabi SwissBiosim and Regeneron Pharmaceuticals, finding that the petitioner failed to meet the required likelihood standard.
Nexus Pharmaceuticals LLC v.Exela Pharma Sciences, LLC
Nexus Pharmaceuticals' PGR challenge against Exela Pharma Sciences was denied institution because the arguments regarding enablement, written description, and obviousness were largely identical to those previously presented during prosecution. The Board found that the Patent Owner successfully demonstrated how process controls overcome prior rejections, leading to a denial of the petition under § 325(d).
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s claims regarding modified PH20 polypeptides in a PTAB decision. The Board instituted trial based on enablement and written description grounds, finding that the broad genus of claimed molecules required undue experimentation to identify active variants.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The PTAB instituted the PGR petition challenging Halozyme's patent covering modified PH20 polypeptides. The Board found that the claims were not sufficiently supported by the specification regarding enablement and obviousness, despite Petitioner's arguments about the genus size.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies Munich SE challenged The Johns Hopkins University's claims regarding FAP-α targeting moieties based on obviousness and patentability issues (103/112). The Board instituted the PGR, finding that the claims face significant challenges related to enablement and indefiniteness.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on enablement and obviousness grounds in a PTAB decision. The Board found that the patent documents supported a broad definition of modified PH20 polypeptides, while noting the petitioner had established a likelihood of prevailing on enablement but failed to prove obviousness.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s '590 patent on grounds of enablement and obviousness. The PTAB found the claims were overly broad regarding polypeptide scope, requiring undue experimentation for a skilled artisan.
AdvanCell Pty Ltd. v.Sciencons AS et al.
AdvanCell Pty Ltd.'s PGR against Sciencons AS et al. was instituted by the PTAB, finding sufficient evidence that several claims are unpatentable. The Board adopted Petitioner's interpretation of a key time-based limitation in Claim 20 during the institution phase.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned for institution in a PGR proceeding against Halozyme, Inc., challenging the '758 patent on grounds of enablement and obviousness. The Board adopted a broad claim construction for 'modified PH20 polypeptide,' which significantly broadened the scope of the challenged claims.
Neurocrine Biosciences, Inc. v.Spruce Biosciences, Inc.
The PTAB denied institution of a PGR for Neurocrine against Spruce because the patent owner had disclaimed all challenged claims.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent claims on grounds of enablement and obviousness. The Board ruled that the claimed modified polypeptides must exhibit hyaluronidase activity, narrowing the scope of the genus. This decision sets a precedent for interpreting functional limitations in polypeptide patents.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme successfully challenged Halozyme's patent claims in a PGR proceeding, focusing on enablement and obviousness. The Board adopted a functional claim construction requiring 'modified PH20 polypeptide' to exhibit hyaluronidase activity.
GE Healthcare Ltd. et al. v.The Johns Hopkins University et al.
GE Healthcare Ltd.'s Post-Grant Review petition against The Johns Hopkins University was instituted by the PTAB, focusing on obviousness and statutory defects. The Board acknowledged strong arguments regarding combining prior art (US-633/Meletta with Jansen) and potential lack of enablement for radiopharmaceutical claims.
Sarepta Therapeutics, Inc et al. v.The Trustees of the University of Pennsylvania et al.
Sarepta Therapeutics challenged patent 11680274, owned by The Trustees of the University of Pennsylvania and Regenxbio Inc., on grounds of obviousness (103). The PTAB ruled in favor of institution, finding that the challenger's arguments were strong enough to warrant further review.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC challenged The Johns Hopkins University's patent (10934356) in an IPR, asserting that all claims are anticipated or obvious. Petitioner relies heavily on the MSI-H Study Record and various prior art references to demonstrate invalidity across multiple grounds. This petition sets up a significant challenge to the scope of PD-1 inhibitor patents for MSI-H cancers.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC challenges The Johns Hopkins University's patent (11325974) in an IPR, arguing that all claims are unpatentable. Petitioner asserts the MSI-H Study Record anticipates the claims under 35 U.S.C. § 102 and various prior art combinations render them obvious under § 103.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC challenged The Johns Hopkins University's patent (11325975) in a Petition, arguing all claims are anticipated by the MSI-H Study Record and rendered obvious by combinations of prior art. The petitioner asserts that the study record inherently discloses every limitation of the claimed method for treating MSI-H patients with anti-PD-1 antibodies.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC challenges the validity of JHU's patent (11,339,219) in an IPR petition. The petitioner asserts that all eight claims are anticipated by or obvious over prior art, primarily citing the MSI-H Study Record and various combinations thereof. This petition seeks to invalidate the core claims related to treating MSI-H tumors with pembrolizumab.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC challenged U.S. Patent No. 11,643,462 in the PTAB, arguing that all claims are anticipated under 35 U.S.C. § 102 and rendered obvious under 35 U.S.C. § 103. The petitioner asserts that the MSI-H Study Record discloses the claimed method of treating MSI-H cancer with pembrolizumab, leading to a request for institution based on compelling evidence.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC challenges U.S. Patent No. 11,629,187 in an IPR proceeding before the PTAB. The petitioner argues that all claims are unpatentable under both anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC petitioned to invalidate U.S. Patent No. 11,634,491 on grounds of anticipation and obviousness in the field of Oncology/Immunotherapy. The petitioner argues that key claims are anticipated by the MSI-H Study Record (EX1005) under 35 U.S.C. § 102. Furthermore, the remaining claims are deemed obvious when combining the MSI-H Study Record with various prior art references like Brown, Duval, Benson, and Koh under 35 U.S.C. § 103.
DR. FALK PHARMA GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH initiated an IPR challenge against Ellodi Pharmaceuticals LP concerning a patent covering oral/topical drug delivery systems. The petition asserts that the challenged claims are obvious under 35 U.S.C. § 103, citing prior art references including Dohil and Grother.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.